IEO_Bonn
@IEO_Bonn
Followers
138
Following
42
Media
1
Statuses
26
Institute of Experimental Oncology - University Hospital Bonn @IEO_HolzelLab @IEO_baldlab @IEO_GloddeLab @ThurleyLab
Bonn
Joined November 2021
We are happy to share our new study published today @JCO_ASCO (👉 https://t.co/NJtUVRVJ0Q) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer. With a huge contribution of our multinational team we uncovered
13
48
147
Very happy to share our study published @JCO_ASCO ! https://t.co/gip2ikcX1G ➡️Patients with mUC with NECTIN4 amplifications (occurring in app. 25%) show remarkable responses to single-agent EV, with a 96% objective response rate compared to 32% in non-amplified cases. NECTIN4
16
39
136
Interesting work from @niklas_kluemper et al —Na levels may module ICB response. Still so much unknown in this area. Congrats for the elegant work Niklas!
We are happy to share our current manuscript: In an exploratory post-hoc analysis of IMmotion151 (mRCC, atezo + beva) and IMvigor211 (mUC, atezo), in which we correlated baseline electrolyte concentration with ICB response and outcome in an unbiased manner, we made an interesting
1
11
22
We are happy to share our current manuscript: In an exploratory post-hoc analysis of IMmotion151 (mRCC, atezo + beva) and IMvigor211 (mUC, atezo), in which we correlated baseline electrolyte concentration with ICB response and outcome in an unbiased manner, we made an interesting
3
17
46
Exciting Update from EV301 trial! 🚀EV maintains survival benefit after ~2 years of follow-up. BUT: Who benefits most from EV?🎯 Our data suggest NECTIN4 as a promising predictive biomarker! @OncoAlert @urotoday @Markuseckstein3 @ViktorGruenwald
https://t.co/JmfOUNobel
#oncology
aacrjournals.org
AbstractPurpose:. The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients...
EV301 Phase III trial update (median follow-up ~2 years): Enfortumab vedotin (EV) maintained survival (HR 0.70, P = 0.00015), PFS (HR 0.63, P < 0.00001) and response rate (41.3% vs. 18.6%) benefit vs. chemotherapy in post-platinum and PD1/L1 inhibitors patients with metastatic
0
10
16
A new research in @JAMANetwork shows that longitudinal measurement of systemic inflammatory response (through mGPS) in patients with mRCC provides valuable prognostic information and could integrate radiological staging in therapy monitoring https://t.co/Y3DKfRGyn8
jamanetwork.com
This prognostic study assesses the prognostic and predictive value of the modified Glasgow prognostic score during treatment in patients with metastatic renal cell carcinoma.
1
8
7
Important work led by @saal_jonas and @niklas_kluemper from @IEO_Bonn just published in @JAMAOnc Developing an Ideal Risk Stratification Model for mRCC 📷Fabulous Editorial from @neerajaiims @ggebraelmd @GliceidaGalarza
https://t.co/yVkCYWhvxs
@KidneyCancer @urotoday @OncoAlert
Happy to share our work: Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma @JAMAOnc. See our tweetorial and the terrific editorial by @ggebraelmd @GliceidaGalarza @neerajaiims @urotoday 1/7
0
0
3
We're grateful to @EUplatinum for featuring our insights on the power of integrating Nectin-4 PET/CT in guiding Nectin-4 targeting therapies like Enfortumab vedotin for patients with met UC. #PrecisionMedicine
https://t.co/jzANCvBtCM Follow our tweetorial 1/6
3
18
46
Congratulations 🥳🎊
We congratulate @susanna_s_ng and @MaikeEffern of @IEO_HolzelLab for beeing selected to participate in this years @lindaunobel Laurate Meeting 👏 https://t.co/KnR0uAoDuI
0
1
12
Happy to share our work: Early CRP kinetics predicts immunotherapy response in NSCLC in the phase III OAK trial @saal_jonas @JNCI_Now
https://t.co/uLYd1ctPt8. Follow our tweetorial about this simple and easy-to-implement immunotherapy biomarker 1/7
academic.oup.com
Abstract. Static biomarkers like programmed death-ligand 1 (PD-L1) are insufficient to accurately predict response to immune checkpoint inhibition. Therefo
1
7
19
Great news in #Tumor #Immunology #research: https://t.co/J5aYDJKEt4 "InterpreTME" recieves funding by @BMBF_Bund to develop new AI tools to analyse the tumor microinvironment. Congratulations to our members @ThurleyLab @IEO_HolzelLab @JanHasenauer and Alexander Effland!
immunosensation.de
The success of cancer treatment depends not only on the type of tumor, but also on the surrounding tissue. Tumors influence it to their advantage, promoting…
0
4
9
Herzlichen Glückwunsch 🎉🎊
(🇬🇧🧵) 🧑🎓Am Freitag wurden die Teilnehmenden des @jugend_forscht Regionalwettbewerbs Bonn/Köln an der @UniBonn geehrt. Wir haben erneut den Sonderpreis #Biomedizin vergeben: Diesmal, ein Tag am @IEO_HolzelLab @UniklinikBonn. Herzlichen Glückwunsch! 🎉 https://t.co/aBvfkMxfjM
0
1
0
Congratulations🎉@niklas_kluemper
Ein Schritt Richtung Präzisionsonkologie - @niklas_kluemper, Urologe des #ukbonn, erhält renommierten C. E. Alken Preis für wissenschaftliche Erkenntnisse zu neuem Krebsmedikament. Cc. @CCR_AACR @Markuseckstein3 @damian_ralser @HolzelMichael @IEO_HolzelLab
0
1
7
Happy to share our work: Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance @CCR_AACR
https://t.co/OmZdl0ETKT Follow our tweetorial about this clinically important data 1/12
7
34
112
In the phase III #IMmotion151 trial of metastatic #RenalCellCarcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. #ReadNow on UroToday > https://t.co/q4vIPEXFqW
@Annals_Oncology @UniklinikBonn @IEO_HolzelLab
0
2
0
The easy-to-implement mGPS performed significantly better than the therapeutically relevant IMDC score @Annals_Oncology. Future trials on mRCC should incorporate the mGPS! Congrats to the leading authors Jonas and Niklas @niklas_kluemper from IEO. @UniklinikBonn @ImmunoSens
Thrilled to share our work on the modified Glasgow prognostic score predicting prognosis in metastatic RCC (IMmotion151 trial) more accurately than the IMDC score! Published in @Annals_Oncology. Thanks to all collaborators! @IEO_HolzelLab @UniklinikBonn
0
0
4
Well done Fenna 👏🥳
Feena Feenstra has again amazed us with how the #CRISPR cas technology could be used to study cancer and the implications in future therapies. And of course, the importance of baking cakes when doing #cloning experiments. 🧬 #pint22 #pint22bonn #pint22de #scicomm #wisskomm #bonn
0
0
4
Interested in learning about science, while have a cool drink? Talented scientists are sharing their latest research today #PintOfScience2022 , including Fenna Feenstra from the @IEO_baldlab @UniBonn
📍📆 Mark your calendars for May 9-11th 2022! We will be back in pubs for #pint22, with local researchers available for discussing their latest #research and answer all your questions in a casual atmosphere 🤓🍻 👉 https://t.co/yQNM6AN6VY 🙌 volunteers welcome, join us!
0
1
3
🔬🦠🧪 Wir kommen zu Euch! 🫁🧬🧫🫀 #Wissenschaft zum Anfassen auf dem Marktplatz #Bonn und in der #Stadtbibliothek Bonn 🗓️ Samstag, 30.04.2022, 10:00 - 18:00 #TagDerImmunologie Programm: https://t.co/KrqRpaYApl
@UniBonn @UniklinikBonn
#dayofimmunology #science #immunology
0
8
11
Longitudinal CRP kinetics (CRP Flare 🔥) predicts immunotherapy response within the first month in NSCLC! Great tool for therapy monitoring and as an integral biomarker for biomarker-directed study design @niklas_kluemper @Doc_Bald @IEO_BaldLab @IEO_Bonn @ImmunoSens @UniBonn
CRP flare 🔥! Longitudinal CRP kinetics predicts response to immunotherapy in NSCLC as early as 4 weeks after therapy start. Simple on-treatment biomarker to optimize monitoring. Chance for early therapy adjustments. Thanks to all collaborators! @docbald @IEO_HolzelLab @UniBonn
0
1
7